Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock

Key Points

• Bicara Therapeutics COO Ryan Cohlhepp sold 12,500 shares at an average price of $18.16, totaling $227,000, which reduced his ownership by 5.93% to about 198,141 shares.
• The company's stock experienced a slight decline of 0.7% during trading, reaching $18.68, with a market capitalization of $1.02 billion.
• Analysts have mixed ratings on the stock, with a consensus target price of $31.86 and varying ratings from "Strong Buy" to "Sell."

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the company's stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $18.16, for a total value of $227,000.00. Following the completion of the transaction, the chief operating officer directly owned 198,141 shares in the company, valued at approximately $3,598,240.56. The trade was a 5.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ryan Cohlhepp also recently made the following trade(s):

• On Tuesday, October 7th, Ryan Cohlhepp sold 10,900 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.06, for a total value of $196,854.00.
• On Monday, October 6th, Ryan Cohlhepp sold 39,600 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.06, for a total value of $715,176.00.

Bicara Therapeutics Stock Down 0.7%

Shares of BCAX traded down $0.13 during trading on Thursday, reaching $18.68. The company's stock had a trading volume of 800,808 shares, compared to its average volume of 583,027. The company has a fifty day moving average of $12.94 and a two-hundred day moving average of $11.97. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $28.09. The company has a market cap of $1.02 billion and a price-to-earnings ratio of -5.89.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04. As a group, equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Nuveen LLC bought a new position in Bicara Therapeutics during the 1st quarter worth $326,000. New York State Common Retirement Fund bought a new position in Bicara Therapeutics during the 1st quarter worth $52,000. GAMMA Investing LLC grew its stake in Bicara Therapeutics by 13,040.7% during the 1st quarter. GAMMA Investing LLC now owns 7,753 shares of the company's stock worth $101,000 after buying an additional 7,694 shares during the last quarter. CWM LLC bought a new position in shares of Bicara Therapeutics in the first quarter worth $29,000. Finally, Atle Fund Management AB grew its stake in shares of Bicara Therapeutics by 23.0% in the second quarter. Atle Fund Management AB now owns 147,380 shares of the company's stock worth $1,369,000 after purchasing an additional 27,547 shares in the last quarter.

Analysts Set New Price Targets

BCAX has been the topic of several research reports. Wedbush reissued an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. HC Wainwright dropped their price target on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday, August 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Bicara Therapeutics in a research report on Tuesday. Finally, Piper Sandler initiated coverage on Bicara Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $36.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $31.86.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.